Citizens Financial Group Inc. RI Buys New Position in Illumina, Inc. $ILMN

Citizens Financial Group Inc. RI bought a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,745 shares of the life sciences company’s stock, valued at approximately $659,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of ILMN. Empowered Funds LLC lifted its position in Illumina by 113.7% in the first quarter. Empowered Funds LLC now owns 9,284 shares of the life sciences company’s stock valued at $737,000 after purchasing an additional 4,940 shares during the period. Sivia Capital Partners LLC acquired a new stake in shares of Illumina in the 2nd quarter worth approximately $621,000. CW Advisors LLC acquired a new stake in shares of Illumina in the 2nd quarter worth approximately $275,000. Marshall Wace LLP increased its stake in Illumina by 49.0% in the 2nd quarter. Marshall Wace LLP now owns 59,645 shares of the life sciences company’s stock valued at $5,691,000 after purchasing an additional 19,618 shares in the last quarter. Finally, Cresset Asset Management LLC raised its holdings in Illumina by 30.9% during the second quarter. Cresset Asset Management LLC now owns 7,404 shares of the life sciences company’s stock worth $706,000 after purchasing an additional 1,748 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insider Buying and Selling

In other Illumina news, Director Keith A. Meister sold 283,269 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $199.61, for a total value of $56,543,325.09. Following the transaction, the director directly owned 2,089,425 shares of the company’s stock, valued at $417,070,124.25. This trade represents a 11.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Scott M. Davies sold 615 shares of the business’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $200.00, for a total value of $123,000.00. Following the transaction, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. This represents a 2.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,415,351 shares of company stock valued at $255,966,311 in the last 90 days. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Performance

Shares of ILMN stock opened at $205.00 on Thursday. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The company has a 50 day moving average price of $185.90 and a 200 day moving average price of $151.49. The firm has a market capitalization of $30.95 billion, a price-to-earnings ratio of 38.25, a price-to-earnings-growth ratio of 2.65 and a beta of 1.45.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The company had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Sell-side analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. Stifel Nicolaus raised their price target on Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Zacks Research upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating in a research report on Monday, August 3rd. Royal Bank Of Canada increased their price objective on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. Piper Sandler restated an “overweight” rating and set a $225.00 target price (up from $200.00) on shares of Illumina in a research report on Monday, August 3rd. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.